Adverse effects of antiepileptic drugs

Epilepsia

Volumn 41, Issue 6 SUPPL. 2, 2000, Pages

  Greenwood, Robert S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects; Antiepileptic drugs; Efficacy; GABA; Weight changes

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; SUCCINIMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADOLESCENT; ADULT; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; WEIGHT GAIN;

EID: 0034040925     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb01523.x     Document Type: Conference Paper

References (84)

1. Brodie MJ, Dichter MA. Established antiepileptic drugs. Seizure 1997;6:159-74.
2. Cramer JA, Fisher R, Ben Menachem E, French J, Mattson RH. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 1999;40:590-600.
3. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313:145-51.
4. Schlienger RG, Oh PI, Knowles SR, Shear NH. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998;39(suppl 7):S27-S32.
5. Food and Drug Administration. Record and reports concerning adverse drug experiences on marketed prescription drugs. Washington, DC: Federal Register; October 7, 1997.
6. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-17.
7. Berkovic SF. Aggravation of generalized epilepsies. Epilepsia 1998;39(suppl 3):S11-S14.
8. Coppola G, Terraciano AM, Pascotto A. Vigabatrin as add-on therapy in children and adolescents with refractory epilepsy: an open trial. Brain Dev 1997;19:459-63.
9. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
10. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
11. Elger CE, Bauer J, Scherrmann J, Widman G. Aggravation of focal epileptic seizures by antiepileptic drugs. Epilepsia 1998;39(suppl 3):S15-S18.
12. Stecker MM, Kita M. Paradoxical response to vulproic acid in a patient with a hypothalamic hamartoma. Ann Pharmacother 1998; 32:1168-72.
13. Jacob PC, Chand RP. Pathological laughter following intravenous sodium valproate. Can J Neurol Sci 1998;25:252-3.
14. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998;39(suppl 3):S2-S10.
15. Ben Menachem E. Vigabatrin. Epilepsia 1995;36(suppl 2):S95-104.
16. Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 1996;25:21-7.
17. Welty TE, Privitera M, Shukla R. Increased seizure frequency associated with felbamate withdrawal in adults. Arch Neurol 1998; 55:641-5.
18. Rowan AJ. Reflections on the treatment of seizures in the elderly population. Neurology 1998;51(suppl 4):S28-S33.
19. Parker BM, Vestal RE. The use of anticonvulsant drugs in the elderly. In: Wyllie E, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea & Febiger, 1997:747-54.
20. Blackburn SC, Oliart AD, Garcia Rodriguez LA, Ferez GS. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998;18:1277-83.
21. Brown WM, Aiken SP. Felbamate: clinical and molecular aspects of a unique antiepileptic drug. Crit Rev Neurobiol 1998;12:205-22.
22. Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39(suppl 7):S22-S26.
23. Pellock JM. Treatment of seizures and epilepsy in children and adolescents. Neurology 1998;51(suppl 4):S8-S14.
24. Bryant AE III, Dreifuss FE. Valproic acid hepatic fatalities, III: US experience since 1986. Neurology 1996;46:465-9.
25. Appleton RE, Farrell K, Applegarth DA, et al. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990;17:145-8.
26. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-54.
27. Konig SA, Schenk M, Sick C, et al. Fatal liver failure associated with valproate therapy in a patient with Friedreich's disease: review of valproate hepatotoxicity in adults. Epilepsia 1999;40: 1036-40.
28. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 1995;68:385-424.
29. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994;102:28S-30S.
30. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39(suppl 7):S8-S16.
31. Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38:1261-4.
32. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997;38:1265-9.
33. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39(suppl 7):S3-S7.
34. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91.
35. Khafaga YM, Jamshed A, Allam AA, et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol 1999;38:111-6.
36. Duncan KO, Tigelaar RE, Bolognia JL. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. J Am Acad Dermatol 1999;40:493-6.
37. Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999;40:341-4.
38. May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993;34:1098-101.
39. Brodie MJ. Drug interactions in epilepsy. Epilepsia 1992;33(suppl 1):S13-S22.
40. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999;24:87-92.
41. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-85.
42. Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press, 1995.
43. Shorvon SD. The treatment of epilepsy. Oxford, England: Blackwell Science, 1996.
44. Wyllie E. The Treatment of epilepsy: principles and practice. 2nd ed. Baltimore, Md: Williams & Wilkins, 1997.
45. Engel J, Pedley TA. Epilepsy: a comprehensive textbook. Philadelphia, Pa: Lippincott-Raven, 1998.
46. Ben Menachem E, Eadie MJ, Vajda FJE. Antiepileptic drugs: pharmacology and therapeutics. Vol 5. Berlin, Germany: Springer, 1999.
47. Biller J. latrogenic neurology. Boston, Ma: Butterworth-Heinemann, 1998.
48. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996;14: 329-42.
49. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
50. Carmel PW. Vegetative dysfunctions of the hypothalamus. Acta Neurochir (Wien) 1985;75:113-21.
51. Leibowitz SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci 1992;15:491-7.
52. Isojarvi JI, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
53. National Center for Health Statistics. Healthy People 2000 Review, 1998-1999. Hyattsville, Maryland: Public Health Service, 1999. DHHS Publication (PHS) 99-1256.
54. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765-71.
55. Isojarvi JI, Rattya J, Myllyla VV et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43:446-51.
56. Morgan JI, Curran T. Calcium and proto-oncogene involvement in the immediate-early response in the nervous system. Ann NY Acad Sci 1989;568:283-90.
57. Novak GP, Maytal J, Alshansky A, et al. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-5.
58. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-93.
59. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999;354:13-9.
60. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine: a reappraisal. Seizure 1997;6:121-5.
61. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
62. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51.
63. Lampl Y, Eshel Y, Rapaport A, Sarova-Pinhas I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991;14:251-5.
64. Carmant L, Holmes GL, Sawyer S, et al. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994;125:481-6.
65. Bergen DC, Ristanovic RK, Waicosky K, Kanner A, Hoeppner TJ. Weight loss in patients taking felbamate. Clin Neuropharmacol 1995;18:23-7.
66. Tartara A, Sartori I, Manni R, et al. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial Ital J Neurol Sci 1996;17:429-32.
67. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl 2):S18-S22.
68. Thomas AB, Matthews GC, Ferrendelli JA. Mechanisms of action of antiepileptic drugs. In: Wyllie E, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea & Febiger, 1997:747-54.
69. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-70.
70. Verrotti A, Basciani F, Morresi S, et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-2.
71. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(suppl 6):S4-S11.
72. Stratford TR, Kelley AE. Evidence of a functional relationship between the nucleus accumbens shell and lateral hypothalamus subserving the control of feeding behavior. J Neurosci 1999;19: 11040-8.
73. Khan AM, Curras MC, Dao J, et al. Lateral hypothalamic NMDA receptor subunits NR2A and/or NR2B mediate eating: immunochemical/behavioral evidence. Am J Physiol 1999;276:R880-R891.
74. Stratford TR, Swanson CJ, Kelley A. Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell. Behav Brain Res 1998;93:43-50.
75. Leber PD. Hazards of inference: the active control investigation. Epilepsia 1989;30(suppl 1):S57-S63.
76. Shorvon S, Stefan H. Overview of the safety of newer antiepileptic drugs. Epilepsia 1997;38(suppl 1):S45-S51.
77. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;(suppl 2):S52-S59.
78. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-4.
79. Felbatol® [package insert]. Abbott Park, Ill: Abbott Laboratories; 2000.
80. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34(suppl 7):S18-S24.
81. Sachdeo RC. Topiramate: clinical profile in epilepsy. Clin Pharmacokinet 1998;34:335-46.
82. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41: 1785-9.
83. Glauser TA. Topiramate. Semin Pediatr Neurol 1997;4:34-42.
84. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52: 1330-7.